Ab-Interno Canaloplasty 12 Month Results
Ab-Interno Canaloplasty (ABiC™) showed very impressive results in the 12 month multi-center, safety and efficacy clinicial study done by Mark J. Gallardo and Mahmoud A. Khaimi, MD.
Their study indicates that ABiC™ is safe and effective in mild-to-moderate Primary Open-Angle Glaucoma (POAG) with similar IOP- lowering effects to traditional Canaloplasty. (If Canaloplasty is new to you, you may want to read this first: What Is Canaloplasty?)
Here are just some of the highlights. You may read the full article here: Ab-interno Canaloplasty – The Minimally Invasive Glaucoma Surgery That Keeps Its Promise
- The reduction in intraocular pressure (IOP) after canaloplasty was 30%
- The number of medications required to keep the IOP under control was reduced by 50%
- Of those who underwent ABiC™ in conjunction with Phacoemulsification, IOP was reduced by 23.39% and glaucoma medication reduced by 50%
- When Ab-Interno Canaloplasty alone is done, intraocular pressure decreased by 36.74% and glaucoma medication was reduced by 66.66% in as early as 3rd month post operation!
- Those with uncontrolled Glaucoma (>16 IOP) already under maximum medical Therapy (+3 gtts), intraocular pressure decreased by 40.46% in IOP and glaucoma medication was also reduced by 66.66%!
These results is also similar with the study of Prof. Noerbert Koerber in Germany and the overall frequency of surgical and postsurgical complications was low and no adverse events were reported.
(Also read: Gold Standard Trabeculectomy Dethroned by Canaloplasty)
References
1)Non-Penetrating Schlemm’s Canaloplasty versus Trabeculectomy: A Head-to- Head Comparison. Tam D, Calafati J, Ahmed I. [Submitted for publication, December 2009].
2) Ayyala RS, Chaudhry AL, Okogbaa CB, et al. Comparison of surgical outcomes between canaloplasty and trabeculectomy at 12 months’ follow-up. Ophthalmology. 2011;118:2427–2433.
3) Schoenberg ED, Chaudhry AL, Chod R, Zurakowski D, Ayyala RS. Comparison of Surgical Outcomes Between Phacocanaloplasty and Phacotrabeculectomy at 12 Months’ Follow-up: A Longitudinal Cohort Study. J Glaucoma. 2015;24(7):543-549.
David Richardson, MD
Medical Director, San Marino Eye
David Richardson, M.D. is recognized as one of the top cataract and glaucoma surgeons in the US and is among an elite group of glaucoma surgeons in the country performing the highly specialized canaloplasty procedure. Morever, Dr. Richardson is one of only a few surgeons in the greater Los Angeles area that performs MicroPulse P3™ "Cyclophotocoagulation" (MP3) glaucoma laser surgery. Dr. Richardson graduated Magna Cum Laude from the University of Southern California and earned his Medical Degree from Harvard Medical School. He completed his ophthalmology residency at the LAC+USC Medical Center/ Doheny Eye Institute. Dr. Richardson is also an Ambassador of Glaucoma Research Foundation.
